Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis' SoloSTAR Lantus insulin pen marketed in US

Sanofi-aventis launches Lantus SoloSTAR, a disposable insulin pen, on the US market

Sanofi-aventis has launched its Lantus SoloSTAR, a disposable insulin pen, on the US market.

SoloSTAR pre-filled with Lantus (insulin glargine [rDNA origin]), the only 24-hour insulin approved exclusively for use once a day, for the treatment of hyperglycaemia in people with type 1 or type 2 diabetes.

The product is also the only prefilled disposable insulin pen which permits patients to administer doses from one to 80 units, in one injection and offers a 25 per cent greater maximum capacity than other insulin pens.

Equivalence studies have revealed that the product operates with a lower injection force and requires 31 per cent less injection force than the Novo Nordisk FlexPen and 54 per cent less force than the Eli Lilly Humulin/Humalog pen.

Lantus SoloSTAR is also available in Australia. Previously, it was introduced in France and Germany in 2007 and is expected to be introduced in other countries in the near future.

Angela Moskow, associate vice president of diabetes marketing at sanofi-aventis, said: "Insulin pens are underutilised in the US, compared with other countries, even though they may offer more convenience and flexibility for people with diabetes. Lantus SoloSTAR demonstrates sanofi-aventis' commitment to designing devices based on insights from people with diabetes, to help meet their lifestyle demands. We are excited to offer this new device."

30th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics